Skip to main content
Top
Published in: Clinical Rheumatology 1/2020

01-01-2020 | Methotrexate | Original Article

Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis

Authors: Clélia Monchablon, Henri Gondé, Sophie Pouplin, Rémi Varin, Olivier Vittecoq, Thierry Lequerré

Published in: Clinical Rheumatology | Issue 1/2020

Login to get access

Abstract

Objectives

This work aimed to assess treatment adherence in rheumatoid arthritis patients with several tools and to identify factors associated with poor adherence.

Method

Between February and December 2015, 183 patients were included in this cross-sectional study. A homemade 23-item self-questionnaire was filled by patients during an outpatient consultation or a day hospitalization stay. Morisky Medication Adherence Scale (MMAS)-4, MMAS-8 and Girerd scores were extracted from this homemade questionnaire. Medication possession ratio (MPR) was then calculated. For identification of factors associated with nonadherence, patients were divided in two groups according to MMAS-8 results differentiating patients with good or bad adherence to treatments.

Results

Of the 183 patients, 59% received a combination of biologic and conventional synthetic disease-modifying drugs, 22% a biological treatment alone, and 19% a conventional DMARD alone. Respectively, 3%, 10%, and 7% were considered as low adherent according to MMAS-4, MMAS-8, and Girerd scores. MPR was calculated for 84/183 patients; 23% were low adherent. The need for a help in preparing the drugs (p = 0.05; OR = 6.12; 95% CI: 0.86 to 268.90) and concomitant diabetes (p < 0.001; OR = 0.045, 95% CI: 0.001 to 0.299) was higher in patients with good adherence. Presence of a patient’s relative reminding to take medications was associated with low adherence (p = 0.002; OR = 4.32, 95% CI: 1.41 to 13.11).

Conclusions

This study highlighted the difficulty of assessing treatment adherence in rheumatoid arthritis patients despite four different tools. Objective measures by MPR indicated a higher proportion of poor adherent patients than self-questionnaires.
Key Points
Proportion of patients considered as low adherent ranged from 3 to 27% according to the method of evaluation.
The use of a pillbox and/or the preparation of drugs by a patient’s relative was associated with good adherence.
The presence of a patient’s relative reminding to take medication was associated with low adherence.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47CrossRef Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47CrossRef
2.
go back to reference Martin LR, Williams SL, Haskard KB, Dimatteo MR (2005) The challenge of patient adherence. Ther Clin Risk Manag 1:189–199PubMedPubMedCentral Martin LR, Williams SL, Haskard KB, Dimatteo MR (2005) The challenge of patient adherence. Ther Clin Risk Manag 1:189–199PubMedPubMedCentral
3.
go back to reference Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497CrossRef Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497CrossRef
4.
go back to reference Scott DL, Wolfe F, Huizinga TWJ (2010) Rheumatoid arthritis. Lancet 376:1094–1108CrossRef Scott DL, Wolfe F, Huizinga TWJ (2010) Rheumatoid arthritis. Lancet 376:1094–1108CrossRef
5.
go back to reference de Achaval S, Suarez-Almazor ME (2010) Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumatol 5:313–326CrossRef de Achaval S, Suarez-Almazor ME (2010) Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumatol 5:313–326CrossRef
6.
go back to reference Contreras-Yáñez I, Ponce De León S, Cabiedes J et al (2010) Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci 340:282–290CrossRef Contreras-Yáñez I, Ponce De León S, Cabiedes J et al (2010) Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci 340:282–290CrossRef
7.
go back to reference Bluett J, Morgan C, Thurston L et al (2015) Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology 54:494–499CrossRef Bluett J, Morgan C, Thurston L et al (2015) Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology 54:494–499CrossRef
8.
go back to reference Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67–74CrossRef Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67–74CrossRef
9.
go back to reference Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 10:348–354CrossRef Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 10:348–354CrossRef
10.
go back to reference Blum MA, Koo D, Doshi JA (2011) Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 33:901–913CrossRef Blum MA, Koo D, Doshi JA (2011) Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 33:901–913CrossRef
11.
go back to reference Tkacz J, Ellis L, Bolge SC, Meyer R, Brady BL, Ruetsch C (2014) Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin Ther 36:737–747CrossRef Tkacz J, Ellis L, Bolge SC, Meyer R, Brady BL, Ruetsch C (2014) Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin Ther 36:737–747CrossRef
12.
go back to reference Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRef Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRef
13.
go back to reference Girerd X, Hanon O, Anagnostopoulos K et al (2001) Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic. Presse Med 30:1044–1048PubMed Girerd X, Hanon O, Anagnostopoulos K et al (2001) Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic. Presse Med 30:1044–1048PubMed
14.
go back to reference Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC (2009) Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 25:2303–2310CrossRef Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC (2009) Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 25:2303–2310CrossRef
15.
go back to reference Gossec L, Molto A, Romand X et al (2019) Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: a process based on literature reviews and expert consensus. Joint Bone Spine 86:13–19CrossRef Gossec L, Molto A, Romand X et al (2019) Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: a process based on literature reviews and expert consensus. Joint Bone Spine 86:13–19CrossRef
17.
go back to reference Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD (2009) Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother 43:413–422CrossRef Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD (2009) Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother 43:413–422CrossRef
18.
go back to reference van den Bemt BJF, Zwikker HE, van den Ende CHM (2012) Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol 8:337–351CrossRef van den Bemt BJF, Zwikker HE, van den Ende CHM (2012) Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol 8:337–351CrossRef
19.
go back to reference Ho PM, Bryson CL, Rumsfeld JS (2009) Medication adherence: its importance in cardiovascular outcomes. Circulation 119:3028–3035CrossRef Ho PM, Bryson CL, Rumsfeld JS (2009) Medication adherence: its importance in cardiovascular outcomes. Circulation 119:3028–3035CrossRef
20.
go back to reference Harley CR, Frytak JR, Tandon N (2003) Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 9:S136–S143PubMed Harley CR, Frytak JR, Tandon N (2003) Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 9:S136–S143PubMed
21.
go back to reference Kristensen LE, Saxne T, Nilsson J-A, Geborek P (2006) Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 8:R174CrossRef Kristensen LE, Saxne T, Nilsson J-A, Geborek P (2006) Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 8:R174CrossRef
22.
go back to reference Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA (2005) Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 118:515–520CrossRef Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA (2005) Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 118:515–520CrossRef
23.
go back to reference Morgan C, McBeth J, Cordingley L, Watson K, Hyrich KL, Symmons DP, Bruce IN (2015) The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology 54:1780–1791CrossRef Morgan C, McBeth J, Cordingley L, Watson K, Hyrich KL, Symmons DP, Bruce IN (2015) The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology 54:1780–1791CrossRef
24.
go back to reference Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, Östör AJ, Peyrin-Biroulet L, Lacerda AP, Weinman J (2015) A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther 32:983–1028CrossRef Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, Östör AJ, Peyrin-Biroulet L, Lacerda AP, Weinman J (2015) A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther 32:983–1028CrossRef
25.
go back to reference Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, Herzer P, Kekow J, Schneider M, Rau R (2005) Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 64:1274–1279CrossRef Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, Herzer P, Kekow J, Schneider M, Rau R (2005) Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 64:1274–1279CrossRef
26.
go back to reference De Cuyper E, De Gucht V, Maes S et al (2016) Determinants of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol 35:1335–1339CrossRef De Cuyper E, De Gucht V, Maes S et al (2016) Determinants of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol 35:1335–1339CrossRef
27.
go back to reference Gadallah MA, Boulos DNK, Gebrel A et al (2015) Assessment of rheumatoid arthritis patients’ adherence to treatment. Am J Med Sci 349:151–156CrossRef Gadallah MA, Boulos DNK, Gebrel A et al (2015) Assessment of rheumatoid arthritis patients’ adherence to treatment. Am J Med Sci 349:151–156CrossRef
28.
go back to reference Anghel L-A, Farcaş AM, Oprean RN (2018) Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. Patient Prefer Adherence 12:1151–1166CrossRef Anghel L-A, Farcaş AM, Oprean RN (2018) Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. Patient Prefer Adherence 12:1151–1166CrossRef
29.
go back to reference Hill J, Bird H, Johnson S (2001) Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 60:869–875PubMedPubMedCentral Hill J, Bird H, Johnson S (2001) Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 60:869–875PubMedPubMedCentral
30.
go back to reference Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R (2008) Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 59:1519–1526CrossRef Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R (2008) Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 59:1519–1526CrossRef
31.
go back to reference Walsh JC, Mandalia S, Gazzard BG (2002) Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 16:269–277CrossRef Walsh JC, Mandalia S, Gazzard BG (2002) Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 16:269–277CrossRef
32.
go back to reference Porteous T, Francis J, Bond C, Hannaford P (2010) Temporal stability of beliefs about medicines: implications for optimising adherence. Patient Educ Couns 79:225–230CrossRef Porteous T, Francis J, Bond C, Hannaford P (2010) Temporal stability of beliefs about medicines: implications for optimising adherence. Patient Educ Couns 79:225–230CrossRef
33.
go back to reference Tijhuis GJ, Kooiman KG, Zwinderman AH, Hazes JM, Breedveld FC, Vliet Vlieland TP (2003) Validation of a novel satisfaction questionnaire for patients with rheumatoid arthritis receiving outpatient clinical nurse specialist care, inpatient care, or day patient team care. Arthritis Rheum 49:193–199CrossRef Tijhuis GJ, Kooiman KG, Zwinderman AH, Hazes JM, Breedveld FC, Vliet Vlieland TP (2003) Validation of a novel satisfaction questionnaire for patients with rheumatoid arthritis receiving outpatient clinical nurse specialist care, inpatient care, or day patient team care. Arthritis Rheum 49:193–199CrossRef
34.
go back to reference Murage MJ, Tongbram V, Feldman SR et al (2018) Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence 12:1483–1503CrossRef Murage MJ, Tongbram V, Feldman SR et al (2018) Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence 12:1483–1503CrossRef
35.
go back to reference Carter CT, Changolkar AK, Scott McKenzie R (2012) Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. J Med Econ 15:332–339CrossRef Carter CT, Changolkar AK, Scott McKenzie R (2012) Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. J Med Econ 15:332–339CrossRef
Metadata
Title
Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
Authors
Clélia Monchablon
Henri Gondé
Sophie Pouplin
Rémi Varin
Olivier Vittecoq
Thierry Lequerré
Publication date
01-01-2020
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 1/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04837-2

Other articles of this Issue 1/2020

Clinical Rheumatology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine